Corrigendum
(Source: The Journal of Pathology)
Source: The Journal of Pathology - February 14, 2018 Category: Pathology Tags: Corrigendum Source Type: research
Issue Information
(Source: The Journal of Pathology)
Source: The Journal of Pathology - February 14, 2018 Category: Pathology Tags: Issue Information Source Type: research
Recent advances and opportunities in proteomic analyses of tumour heterogeneity
Abstract
Solid tumour malignancies comprise a highly variable admixture of tumour and non‐tumour cellular populations, forming a complex cellular ecosystem and tumour microenvironment. This tumour heterogeneity is not incidental, and is known to correlate with poor patient prognosis for many cancer types. Indeed, non‐malignant cell populations, such as vascular endothelial and immune cells, are known to play key roles supporting and, in some cases, driving aggressive tumour biology, and represent targets of emerging therapeutics, such as antiangiogenesis and immune checkpoint inhibitors. The biochemical interplay betwe...
Source: The Journal of Pathology - February 14, 2018 Category: Pathology Authors: Nicholas W Bateman, Thomas P Conrads Tags: Invited Review Source Type: research
Established, emerging and elusive molecular targets in the treatment of lung cancer
Abstract
Although histological subtype still underlies tumour classification and treatment, the recognition that lung cancer is, largely, a genetic disease has prompted a push to reconfigure cancer taxonomies according to molecular criteria. In this review, we discuss established (e.g. EGFR, ALK, ROS1, and programmed cell death 1/programmed death‐ligand 1), emerging (e.g. MET, RET, and NTRK) and elusive (e.g. TP53, KRAS, and MYC) molecular targets in the treatment of lung cancer. We synthesize a large and rapidly growing body of literature regarding the discovery and therapeutic inhibition of these targets in lung cancer...
Source: The Journal of Pathology - February 14, 2018 Category: Pathology Authors: Jean ‐Nicolas Gallant, Christine M Lovly Tags: Invited Review Source Type: research
The molecular pathology of cancer: from pan ‐genomics to post‐genomics
The Journal of Pathology,Volume 244, Issue 5, Page 509-511, April 2018. (Source: The Journal of Pathology)
Source: The Journal of Pathology - February 13, 2018 Category: Pathology Source Type: research
Transcriptomic definition of molecular subgroups of small round cell sarcomas
This study also refined the characteristics of some entities such as EWSR1‐PATZ1 spindle cell sarcoma or FUS‐NFATC2 bone tumours that are different from EWSR1‐NFATC2 tumours and transcriptionally resemble CIC‐fused tumour entities. We also describe a completely novel group of epithelioid and spindle‐cell rhabdomyosarcomas characterized by EWSR1‐ or FUS‐TFCP2 fusions. Finally, expression data identified some potentially new therapeutic targets or pathways. (Source: The Journal of Pathology)
Source: The Journal of Pathology - February 12, 2018 Category: Pathology Authors: Sarah Watson, Virginie Perrin, Delphine Guillemot, Stephanie Reynaud, Jean ‐Michel Coindre, Marie Karanian, Jean‐Marc Guinebretière, Paul Freneaux, François Le Loarer, Megane Bouvet, Louise Galmiche‐Rolland, Frédérique Larousserie, Elisabeth Lon Tags: Original Paper Source Type: research
N ‐glycosylation by N‐acetylglucosaminyltransferase V Enhances the Interaction of CD147/Basigin with Integrin β1 and Promotes HCC Metastasis
Abstract
While the importance of protein N‐glycosylation in cancer cell migration is well appreciated, the precise mechanisms by which N‐acetylglucosaminyltransferase V (GnT‐V) regulates cancer processes remain largely unknown. In the current study, we report that GnT‐V mediated N‐glycosylation of CD147/Basigin, a tumor‐associated glycoprotein that carries β1,6 N‐acetylglucosamine (β1,6 GlcNAc) glycans, is upregulated during TGF‐β1‐induced epithelial‐to‐mesenchymal transition (EMT), which correlates with tumor metastasis in patients with hepatocellular carcinoma (HCC). Interruption of β1,6 GlcNAc ...
Source: The Journal of Pathology - February 12, 2018 Category: Pathology Authors: Jian Cui, Wan Huang, Bo Wu, Jin Jin, Lin Jing, Wen ‐Pu Shi, Zhen‐Yu Liu, Lin Yuan, Dan Luo, Ling Li, Zhi‐Nan Chen, Jian‐Li Jiang Tags: Original Paper Source Type: research
Ruthenium counterstaining for imaging mass cytometry
The Journal of Pathology,Volume 244, Issue 4, Page 479-484, April 2018. (Source: The Journal of Pathology)
Source: The Journal of Pathology - February 5, 2018 Category: Pathology Source Type: research
---
The Journal of Pathology, Ahead of Print. (Source: The Journal of Pathology)
Source: The Journal of Pathology - February 5, 2018 Category: Pathology Source Type: research
The Molecular Pathology of Cancer: From Pan ‐genomics to Post‐genomics
Abstract
As the cancer genomics of most major cancer types have been comprehensively catalogued over the past decade through a variety of national and international efforts, the delineation of cancer subtypes has been refined, and our understanding of critical cancer drivers and of the potentially targetable vulnerabilities they create has grown tremendously. The 2018 Annual Review Issue of The Journal of Pathology provides in‐depth assessments of how these pan‐genomic approaches have enabled advances in cancer classification, targeted therapy selection, and assessment of cancer progression, all of which are now genomi...
Source: The Journal of Pathology - February 1, 2018 Category: Pathology Authors: David G Huntsman, Marc Ladanyi Tags: Invited Review Source Type: research
The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non ‐human primate model of Alzheimer's disease
Abstract
Alzheimer's disease (AD) is a devastating neurological disorder that still lacks an effective treatment, and this has stimulated an intense pursuit of disease‐modifying therapeutics. Given the increasingly recognized link between AD and defective brain insulin signaling, we investigated the actions of liraglutide, a glucagon‐like peptide‐1 (GLP‐1) analog marketed for treatment of type 2 diabetes, in experimental models of AD. Insulin receptor pathology is an important feature of AD brains that impairs the neuroprotective actions of central insulin signaling. Here, we show that liraglutide prevented the los...
Source: The Journal of Pathology - February 1, 2018 Category: Pathology Authors: Andre F. Batista, Leticia Forny ‐Germano, Julia R. Clarke, Natalia M. Lyra e Silva, Jordano Brito‐Moreira, Susan E. Boehnke, Andrew Winterborn, Brian C. Coe, Ann Lablans, Juliana F. Vital, Suelen A. Marques, Ana M. B Martinez, Matthias Gralle, Christi Tags: Original Paper Source Type: research
Molecular analysis of PALB2 associated breast cancers
Abstract
PALB2 is established as the most clinically important moderate to high penetrance breast cancer predisposition gene after BRCA1 and BRCA2. Mutations in classical familial cancer predisposition genes are presumed to be recessive at the cellular level and therefore a second inactivating somatic mutation is required in the tumour tissue. However, from the limited data that exists, PALB2 may be an example of a cancer predisposition gene that does not conform to Knudsen's “two hit” paradigm. We conducted genome‐wide copy number analysis and targeted sequencing of PALB2 and other breast cancer driver genes in 15 i...
Source: The Journal of Pathology - February 1, 2018 Category: Pathology Authors: Jue Er Amanda Lee, Na Li, Simone M. Rowley, Dane Cheasley, Magnus Zethoven, Simone McInerny, Kylie L. Gorringe, Paul A. James, Ian G. Campbell Tags: Original Paper Source Type: research
Prospective patient stratification into robust cancer ‐cell intrinsic subtypes from colorectal cancer biopsies
In this study, we undertook a comprehensive assessment of the robustness of CRC transcriptional signatures, including CRIS and CMS, using a range of tumour sampling methodologies currently employed in clinical and translational research. These include analyses using (i) laser‐capture microdissected CRC tissue, (ii) eight publically available rectal cancer biopsy data sets (n=543), (iii) serial biopsies (from AXEBeam trial, NCT00828672; n=10), (iv) multi‐regional biopsies from colon tumours (n=29 biopsies, n=7 tumours) and (v) pre‐treatment biopsies from the phase II rectal cancer trial COPERNCIUS (NCT01263171; n=44)....
Source: The Journal of Pathology - February 1, 2018 Category: Pathology Authors: Matthew Alderdice, Susan D Richman, Simon Gollins, Peter Stewart, Chris Hurt, Richard Adams, Amy McCorry, Aideen Roddy, Dale Vimalachandran, Claudio Isella, Enzo Medico, Tim Maughan, Darragh G McArt, Mark Lawler, Philip D Dunne Tags: Original Paper Source Type: research
Ruthenium Counterstaining for Imaging Mass Cytometry
ABSTRACT
Imaging mass cytometry is a novel imaging modality that enables simultaneous antibody‐based detection of more than 40 epitopes and molecules in tissue sections at subcellular resolution using isotopically pure metal tags. Essential for any imaging approach where antigen detection is performed is the so‐called counterstaining that reveals the overall structure of the tissue. Counterstaining is necessary since antigens of interest are often present only in a small subset of cells while the rest of tissue structures are not visible. Since most biological tissues are nearly transparent or non‐fluorescent, chromo...
Source: The Journal of Pathology - February 1, 2018 Category: Pathology Authors: Ra úl Catena, Luis M. Montuenga, Bernd Bodenmiller Tags: Original Paper Source Type: research
Donor ‐derived, metastatic urothelial cancer after kidney transplantation associated with a potentially oncogenic BK polyomavirus
Abstract
BK polyomavirus has been linked to urothelial carcinoma in immunosuppressed patients. Here, we performed comprehensive genomic analysis of a BK polyomavirus‐associated, metachronous, multifocal and metastatic micropapillary urothelial cancer in a kidney transplant recipient. Dissecting cancer heterogeneity by sorting technologies prior to array‐comparative genomic hybridization followed by short tandem repeat analysis revealed that the metastatic urothelial cancer was of donor origin (4‐year‐old male). The top 50 cancer‐associated genes showed no key driver mutations as assessed by next‐generation sequ...
Source: The Journal of Pathology - February 1, 2018 Category: Pathology Authors: David C M üller, Maarit Rämö, Klaudia Naegele, Sebastian Ribi, Christian Wetterauer, Valeria Perrina, Luca Quagliata, Tatjana Vlajnic, Christian Ruiz, Beate Balitzki, Rainer Grobholz, Rainer Gosert, Elvis T Ajuh, Hans H Hirsch, Lukas Bubendorf, Cyrill Tags: Brief Definitive Report Source Type: research
